Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Surrogate endpoints and FDA's accelerated approval process.

Thomas R Fleming1

  • 1Department of Biostatistics, University of Washington, Seattle, USA. tfleming@u.washington.edu

Health Affairs (Project Hope)
|January 14, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Select Contemporary Statistical Concepts in Heart Failure Clinical Trials: Insights From the Heart Failure Collaboratory.

JACC. Heart failure·2026
Same author

Defining Cardiovascular Endpoints in Oncology Trials: Challenges and Opportunities: A Scientific Statement From the American Heart Association.

Circulation·2026
Same author

Defining Cardiovascular Endpoints in Oncology Trials: Challenges and Opportunities: A Scientific Statement From the American Heart Association.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

The federated trials approach; an opportunity for global collaboration in health emergencies.

EClinicalMedicine·2026
Same author

Monitoring overall survival in pivotal trials in indolent cancers.

Statistics in biopharmaceutical research·2025
Same author

A Perspective on the Appropriate Implementation of ICH E9(R1) Addendum Strategies for Handling Intercurrent Events.

Statistics in medicine·2025
Same journal

National Health Expenditure Projections, 2025-34: Strong Utilization Growth Initially, Legislative Impacts Later.

Health affairs (Project Hope)·2026
Same journal

State Medicaid Programs Face Increased Spending On Medicare Premiums.

Health affairs (Project Hope)·2026
Same journal

Medicaid Tobacco And Nicotine Cessation Treatment Rates Remained Low, 2019-24.

Health affairs (Project Hope)·2026
Same journal

Third-Party Convener Firms And The Rise Of Geographically Dispersed, High-Earning Medicare ACOs.

Health affairs (Project Hope)·2026
Same journal

The Opacity Of Price Transparency.

Health affairs (Project Hope)·2026
Same journal

Pre-Claim Review And Traditional Medicare Home Health Spending: Evidence From 4 States.

Health affairs (Project Hope)·2026
See all related articles

The accelerated-approval process enables faster access to new medical interventions for severe diseases. It relies on surrogate endpoints, requiring careful evaluation of safety and efficacy for public health.

Area of Science:

  • Regulatory Science
  • Clinical Pharmacology
  • Public Health

Background:

  • Interest exists in expediting the availability of new medical interventions, especially for life-threatening or serious illnesses.
  • The accelerated-approval pathway allows marketing of interventions based on surrogate endpoints that predict clinical benefit.

Purpose of the Study:

  • To discuss the challenges and considerations for utilizing surrogate endpoints within the accelerated-approval process.
  • To ensure the reliable and timely evaluation of intervention safety and efficacy.

Main Methods:

  • Review of regulatory frameworks and scientific principles governing accelerated approval.
  • Analysis of the role and validation of surrogate endpoints in drug approval.

Related Experiment Videos

Main Results:

  • Accelerated approval offers a pathway for rapid access to novel therapies.
  • Surrogate endpoints must be robust predictors of clinical benefit to ensure patient safety.

Conclusions:

  • Careful management of the accelerated-approval process is crucial.
  • Addressing challenges in surrogate endpoint validation is essential for safeguarding public health and ensuring reliable intervention assessment.